Pharmaceutical manufacturers of Enalapril

Dr. Reddy’s Laboratories Ltd. functions as an integrated pharmaceutical firm, dedicated to supplying cost-effective and innovative medications to promote healthier lifestyles. With a focus on Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products, Dr. Reddy’s delivers a range of products and services such as APIs, customized pharmaceutical services, generics, biosimilars, and distinct formulations. The primary therapeutic areas of concentration encompass gastro-intestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s has a presence in various global markets, with significant engagements in the USA, Europe, India, Russia, and other CIS nations.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

For more than 40 years, Apotex has been a reputable name in the Canadian pharmaceutical industry, offering patients increased availability to high-quality, cost-effective medications

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

At Esteve Quimica, we are dedicated to the healthcare sector by providing support for the advancement and commercialization of products that enhance the health of patients. Established in 1966, our company remains privately owned despite being a part of ESTEVE, one of the largest pharmaceutical groups in Spain. Our current focus is on the development and production of small molecule intermediates and active ingredients for innovator companies, operating as a dedicated third-party contract business.

Dream that drives us at Nosch. The laudable goal that we aim for. The vision that suffuses us with the passion to innovate and excel. Over the past twenty one years, we have been ceaselessly engaged in a quest to sustain and improve the quality of life through creating safe pharmaceutical solutions. Our competencies have grown to embrace the entire pharmaceutical value chain-APIs and semi-finished Formulations. Today, with an impeccable reputation for uncompromising quality and timely delivery, Nosch has emerged as the partner of choice across the world.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

Aarti Pharmalabs Limited, also known as APL, is a prominent Indian producer of Pharmaceuticals and Nutraceuticals with an international presence. Our product range includes Generic APIs, Intermediates, and Xanthine derivatives such as Caffeine. We specialize in providing CDMO services for small molecule drug substances, focusing on process development and manufacturing for both clinical and commercial phase projects intended for Innovator companies. Additionally, we have specialized facilities dedicated to the manufacturing of HPAPIs, Corticosteroids, and Cytotoxic and Oncology products.

Hua Hai Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company offering a comprehensive range of products and services. They specialize in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, injectables, and oral solutions. Their product portfolio addresses various therapeutic areas such as cardiovascular health, anti-infectives, and central nervous system disorders. The company is committed to innovation through significant investment in research and development, aiming to discover new treatments and enhance existing ones. With state-of-the-art manufacturing facilities adhering to international quality standards, Hua Hai Pharmaceutical is dedicated to delivering high-quality and effective pharmaceutical solutions to global markets.

Medichem is a vertically integrated pharmaceutical company. We specialize in the development and manufacture of APIs and FDFs for the global generics industry. Our portfolio includes around 45 APIs and 20 FDFs, and we are a world leader in Chlorhexidine products. With nearly half a century of industry experience, we guarantee the highest standards of quality, operational excellence and respect for the environment. Medichem is headquartered in Spain, with a team of around 400 talented individuals in locations including the USA, Malta and China. We serve over 600 corporate customers in more than 60 countries worldwide.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Inke S.A., a wholly owned subsidiary of Neuraxpharm, has been dedicated to the development and production of high-quality Active Pharmaceutical Ingredients (APIs) with intricate synthesis processes, primarily for application in respiratory and central nervous system (CNS) therapies since 1980. The company, based in Barcelona (Spain) and with over two decades of expertise in micronization, has been continuously expanding internationally since 1998, supplying APIs globally, including the US, Europe, and Japan. Inke has been consistently recognized for its quality and has undergone successful inspections by major global authorities, with the most recent US-FDA inspection taking place in May 2019. Over the past twenty years, the company has made significant progress in establishing itself as a reputable provider of respiratory APIs for inhalation.

Srini Pharmaceuticals Pvt. Ltd., was established in 1995. USFDA, TGA and KFDA approved fully integrated global pharmaceutical company, located just about 60 KM's away from the Pharma Capital of India, Hyderabad. Our manufacturing facility has five fully equipped production blocks with most efficient functional utilities with multiple clean rooms having the ability to produce 10 API's at a time, supported by central quality control laborites with all sophisticated instruments by maintaining complete QMS. The state-of-the-Art Research and development laboratory recognized and approved by Department of Science and Technology, Government of India.

Sri Krishna Pharmaceuticals Ltd (SKPL), established in 1974, started life as a pioneer in the bulk manufacture of acetaminophen (Paracetamol) for the domestic Indian market. Today, the company is a vertically integrated bulk manufacturer of multiple first-line-of-defence APIs, PFIs and finished dosage drugs. Paracetamol is still very important to the company and the company remains one of the largest manufacturers in the world. The role of Indian bulk drug manufacturers in the global pharma supply chain has evolved greatly, with SKPL increasing its presence in the synthesis of bulk APIs, direct compression, intermediate and finished dosage products.

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu province, China, Changzhou pharmaceutical Factory has a rich history & Lineage in the pharmaceutical sector. The company was founded in 1949 by (Tan Ruiting) with a registered capital 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of Shanghai Pharma Group. The Chinese business of Changzhou pharmaceutical factory was full fledged sales & marketing organization,Changzhou Pharma is a one of the prominent players in the Chinese pharmaceutical formulations market with a strong foothold across multiple therapies. The company have more than 1500 employees across the country and has earned a reputation amongest the Chinese pharmaceutical companies for providing innovative, comprehensive and complete healthcare solutions. At Changzhou pharmaceutical Factory, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach across US, Europe, the Asia Pacific region and emerging markets. Our high quality manufacturing dedicated facilities for Oncology, Non Oncology, Complex Generics, OTC-Products and sterile injectables, scientific excellence and vast supply chain network to improve access to medicine for patients worldwide. The company mainly involves leading pharmaceutical manufacturer a wide range of key Intermediates, Active pharmaceutical ingredients, Finished Formulations meet with global standards, Changzhou Pharmaceutical Factory it covers an area of 300,000㎡ including R&D, dedicated manufacturing, international marketing office. And we maintain an industry -leading pipeline, composed of numerous complex generics and state owned brands. The company annually brings 800 tons of API's and 3000 millions of Finished dosage forms across the Globe.

DONGBANG FTL originated under the name Dongbang Synthetic Chemical with the aim of becoming the most well-known and reliable company in the active ingredients sector through honest competition